Cardiac Regeneration Technologies, LLC (CRT), a clinical stage company and a subsidiary of TRT, is committed to neovascularization and increasing collateral pathways within the myocardium. The use of shockwave therapy directly on the surface of the heart shows preliminary results of increased blood flow, increase in the ejection fraction and a marked improvement in cardiac performance.
CRT is nearing completion of its initial animal trials using our MultiWave™ technology to treat cardiovascular disease in rat and pig hearts. Dr. Michael Grimm of the University of Vienna is directing these studies and has already submitted his protocol for human treatment to the Ethical Committee for approval.
For more information about CRT, please contact us at firstname.lastname@example.org.
This device is not yet approved for distribution or use in the United States.
Dr. Michael Grimm of the University of Vienna using CardioGold to regenerate heart tissue cells.